Our Leadership
An open, experienced, and passionate team
-
Robert Ang, MBBS, MBA
President and Chief Executive Officer
Robert Ang, MBBS, MBA, is President and CEO at Vor Bio since 2019. Prior to Vor Bio, Robert gained operational experience focused on strategy and business development through roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also has biotech ...
-
Eyal Attar, MD
Chief Medical Officer
Eyal C. Attar, MD brings more than 20 years of demonstrated clinical excellence to his role at Vor Bio, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies. Prior to joining Vor Bio, Eyal served as ...
-
Tirtha Chakraborty, PhD
Chief Scientific Officer
Tirtha Chakraborty, PhD brings extensive expertise in nucleic acid therapy as well as cell and gene therapy to his role as Chief Scientific Officer. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology. Prior to Sana, he served ...
-
Han Choi, MD, LLM
Chief Financial Officer
Han Choi, MD, LLM brings to Vor Bio over 20 years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. Prior to joining Vor Bio, Han served as a Principal at Oracle Investment Management, Inc. ...
-
John King, MBA
Chief Commercial Officer and Head of Business Development
John King, MBA is a senior commercial leader with over 20 years of experience in biotechnology and rare diseases. Prior to Vor Bio, John served as Chief Commercial Officer at Ra Pharma until August 2020, following its acquisition by UCB. During his time with Ra Pharma, ...
-
Tania Philipp
Chief People Officer
Tania Philipp, Chief People Officer, brings more than 20 years of experience helping early-stage life sciences companies grow and progress. As a member of the senior leadership team, she is responsible for building a skilled and experienced team that will help Vor Bio achieve its ...
-
David Phillips, MBA
Senior Vice President, Head of Quality
David Phillips has more than 28 years of extensive expertise in establishing the foundations of quality departments in multiple pharmaceutical and biotech companies. Prior to joining Vor Bio, David served as Vice President, Head of Quality at Beam Therapeutics where he built the quality management ...
-
Samir Vattompadam, MS
Senior Vice President, Portfolio Strategy and Program Management
Samir Vattompadam brings deep cross-functional experience that spans commercial and clinical development, global-US-affiliate based roles, and small, medium, and large organizations across the pharmaceutical and biotech industry. Before joining Vor Bio, Samir served as Vice President, Program Executive for EQRx where he led cross-functional ...
President and Chief Executive Officer
Robert Ang, MBBS, MBA
Robert Ang, MBBS, MBA, is President and CEO at Vor Bio since 2019. Prior to Vor Bio, Robert gained operational experience focused on strategy and business development through roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also has biotech venture capital experience at Frazier Healthcare Ventures, where he invested in companies such as Incline Therapeutics (now Novartis) and Alnara Pharmaceuticals (now Eli Lilly), and strategy consulting experience at the Boston Consulting Group. He also has general surgery training and his clinical practice centered around soft tissue surgery with an emphasis on solid organ transplants. He received his medical degree at the University of Western Australia and has an MBA with Honors from Columbia Business School. Robert also serves as an independent director at the early-stage cancer immunotherapy company Enara Bio, a member of the Board of Directors and the Executive Committee of the Alliance for Regenerative Medicine, and a member of the Healthcare and Pharmaceutical Management Advisory Board of Columbia Business School.
Learn more about Robert’s views on the industry, the workplace, and other business topics in his CEO Perspectives blog.
Chief Medical Officer
Eyal Attar, MD
Eyal C. Attar, MD brings more than 20 years of demonstrated clinical excellence to his role at Vor Bio, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies. Prior to joining Vor Bio, Eyal served as senior vice president and CMO for Aprea Therapeutics where he led development of Aprea’s lead programs, including overseeing clinical development, pharmacovigilance, and regulatory filings. Eyal worked closely on APR-246 (eprenetapopt), a cancer therapeutic pursuing indications including myelodysplastic syndromes (MDS), AML, and various solid tumors. Before Aprea, he held multiple positions in clinical development at Agios Pharmaceuticals, including Senior Medical Director and IDH Hematology Medical Lead, where he worked on various solid tumor and hematologic malignancy programs and contributed to the successful filing of multiple INDs. Eyal has played a leadership role in all aspects of clinical development from Pre-IND through to marketing authorization for several products to treat patients with newly diagnosed and relapsed/refractory AML.
Eyal was previously an attending hematologist/oncologist at Massachusetts General Hospital focusing on leukemia, MDS, and other hematologic malignancies affecting the bone marrow. He completed fellowship training at Dana-Farber Cancer Center and residency at Brigham and Women’s Hospital. Eyal received his medical degree from the University of North Carolina School of Medicine.
Chief Scientific Officer
Tirtha Chakraborty, PhD
Tirtha Chakraborty, PhD brings extensive expertise in nucleic acid therapy as well as cell and gene therapy to his role as Chief Scientific Officer. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology. Prior to Sana, he served as the Head of Hematology at CRISPR Therapeutics, leading research on hemoglobin disorders. His team’s work on autologous cell therapy using gene edited hematopoietic stem cells paved the way to the first approved CRISPR engineered product, Casgevy, a treatment for Sickle Cell Disease. Before that, Tirtha built the mRNA platform at Moderna Therapeutics. In his academic life, he was trained as a molecular geneticist and focused on the role of small RNAs in lymphocyte development and lymphomagenesis in the laboratory of Professor Klaus Rajewsky at Harvard Medical School. Tirtha’s PhD thesis was on deciphering the molecular mechanism of naturally acquired immunity against the malarial parasite Plasmodium falciparum. Tirtha serves as a Scientific Advisory Board Member of Specific Biologics, a genome editing company, and as a Board Member and Scientific Advisory Board Member of the Belgium based DROIA Venture company, Vedra Therapeutics, focused on mitochondrial genome editing and delivery. In addition to his CSO responsibilities, he also oversees Technical Operations at Vor Bio.
Chief Financial Officer
Han Choi, MD, LLM
Han Choi, MD, LLM brings to Vor Bio over 20 years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. Prior to joining Vor Bio, Han served as a Principal at Oracle Investment Management, Inc. until September 2024, where he managed its healthcare public and private equity portfolios. For over two decades at Oracle, Han was responsible for sourcing, negotiating, and managing investments in the pharmaceutical and biotechnology sectors and provided strategic advice to portfolio companies on clinical, business development, and capital market strategies. Prior to joining Oracle, he held positions of increasing responsibility in licensing and business development at Pharmacia Corporation and Bristol-Myers Squibb Company. Han received his M.D. from The Mount Sinai School of Medicine and holds law degrees from Harvard Law School, and Oxford University. He is also a licensed physician in New York State and a member of the New York State Bar, Third Judicial Department.
Chief Commercial Officer and Head of Business Development
John King, MBA
John King, MBA is a senior commercial leader with over 20 years of experience in biotechnology and rare diseases. Prior to Vor Bio, John served as Chief Commercial Officer at Ra Pharma until August 2020, following its acquisition by UCB. During his time with Ra Pharma, John led the organization in preparing for a global commercial launch. Prior to Ra Pharma, he was Vice President, U.S. Neurology Business Unit, at Alexion Pharmaceuticals where he was responsible for building and leading the team that launched Soliris® (eculizumab) for gMG. At Alexion, he also served roles of increasing responsibility, including Vice President, Head of Global LAL-D Franchise and Vice President, Head of Global Hematology Franchise. Before joining Alexion in 2009, John served in commercial roles of increasing responsibility at Wyeth Pharmaceuticals, including Product Director of Enbrel® (etanercept). He began his career at Ernst & Young LLP. John obtained his B.S. in business logistics and MBA from the Pennsylvania State University.
Chief People Officer
Tania Philipp
Tania Philipp, Chief People Officer, brings more than 20 years of experience helping early-stage life sciences companies grow and progress. As a member of the senior leadership team, she is responsible for building a skilled and experienced team that will help Vor Bio achieve its objectives. Tania has a passion for creating a collaborative company culture and for fostering team dynamics that support individual and organizational growth. Prior to joining Vor Bio, she was Vice President and Head of Human Resources at Tango Therapeutics, where she was responsible for developing and implementing the strategic human resources vision that supported the company’s objectives and defined its culture. Before Tango, Tania held various senior human resources positions for a number of companies, including Bavarian Nordic, Mendel Biotechnology, Sunesis Pharmaceuticals, Pearl Therapeutics (acquired by AstraZeneca), and Protein Design Labs. Tania holds a master’s degree in behavioral psychology from The University of the Pacific.
Senior Vice President, Head of Quality
David Phillips, MBA
David Phillips has more than 28 years of extensive expertise in establishing the foundations of quality departments in multiple pharmaceutical and biotech companies. Prior to joining Vor Bio, David served as Vice President, Head of Quality at Beam Therapeutics where he built the quality management system from the ground up, spanning all GxP areas. He also served as Vice President, Head of Quality at Kiniksa Pharmaceuticals where he established the company’s overall strategic long-term vision for quality. Before Kiniksa, David was Vice President, Quality at Shire Pharmaceuticals prior to its acquisition by Takeda. Notably, David was a core member of the team responsible for the integration of a number of programs and companies acquired by Shire and was responsible for various aspects of quality product lifecycle planning, quality aspects of geographic expansion, and technical oversight of key quality functions across a network of more than 25 locations.
David’s experience working outside of the United States – at Lonza Biologics in Singapore and at VaxGen, Inc./Celltrion in South Korea– provides him with a valuable global perspective. While at Lonza, he helped establish the country’s first biologics manufacturing park. David holds an MBA in new product development and project management and a Bachelor of Science in biochemistry and polymer chemistry from the North Carolina State University.
Senior Vice President, Portfolio Strategy and Program Management
Samir Vattompadam, MS
Samir Vattompadam brings deep cross-functional experience that spans commercial and clinical development, global-US-affiliate based roles, and small, medium, and large organizations across the pharmaceutical and biotech industry. Before joining Vor Bio, Samir served as Vice President, Program Executive for EQRx where he led cross-functional program strategy teams, including external partners, for lead candidates in immuno-oncology from late-stage studies through to regulatory submissions, including the company’s first marketing authorization applications to the MHRA and EMA for Sugemalimab in metastatic non-small cell lung cancer. Prior to EQRx, he was Executive Director, Product Team Leader at Seagen for several late-stage ADCs including TIVDAK, PADCEV, and ADCETRIS and collaborated with development partners at Genmab, Astellas, and Takeda. Samir led cross-functional teams focusing on the development, submission, and approval for TIVDAK in metastatic cervical cancer. Earlier in his career, Samir served at Roche in various roles including the Global Commercial Director for GU cancers for TECENTRIQ (atezolizumab), Global Product Manager for GAZYVA (obinutuzumab) in lymphomas, and roles spanning oncology marketing, sales, and medical affairs at Roche Canada. Samir holds a Masters in Medical Sciences and a Bachelor of Science in Biology from McMaster University.